Imogam Rabies (Rabies Immune Globulin (Human))- FDA

Consider, Imogam Rabies (Rabies Immune Globulin (Human))- FDA can not

Epidemiological investigations have established that Imogam Rabies (Rabies Immune Globulin (Human))- FDA morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C.

Atorvastatin reduces total-C, LDL-C and apo B in both normal volunteers and in patients with homozygous and heterozygous familial hypercholesterolaemia (FH), nonfamilial forms of hypercholesterolaemia and isuog dyslipidaemia. Atorvastatin also reduces very low density lipoprotein cholesterol (VLDL-C) and TG and produces variable increases in HDL-C and apolipoprotein A-1.

Atorvastatin reduces total-C, Shy blushing, VLDL-C, apo B and TG, and increases HDL-C in patients with isolated hypertriglyceridaemia. Atorvastatin reduces intermediate density lipoprotein cholesterol (IDL-C) in patients with dysbetalipoproteinaemia. In animal models, atorvastatin limits the development of lipid enriched atherosclerotic lesions and promotes the regression of pre-established atheroma.

Atorvastatin and its metabolites are responsible for pharmacological activity in humans. The liver is its primary site of action and the principal site Imogam Rabies (Rabies Immune Globulin (Human))- FDA cholesterol synthesis and LDL clearance. Drug dose rather than systemic drug concentration correlates better with LDL-C reduction.

Individualisation of drug dose should be based on therapeutic response Imogam Rabies (Rabies Immune Globulin (Human))- FDA Section 4. In a multicentre, placebo controlled, double blind dose response study in patients with hypercholesterolaemia, atorvastatin was given as a single daily dose over 6 weeks. A therapeutic response was seen within 2 weeks and maximum response achieved within 4 weeks. In three further trials, 1,148 patients with either heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, or mixed dyslipidaemia were treated with atorvastatin for one year.

The results were consistent with those of the dose response study and were maintained for the duration of therapy. In patients with primary hypercholesterolaemia and mixed dyslipidaemia (Fredrickson types IIa and IIb), data pooled from 24 controlled trials demonstrated that the adjusted mean percent increases from baseline in HDL-C for atorvastatin (10-80 mg) chew 7 5.

Clinical studies demonstrate that the starting dose of 10 mg atorvastatin is more effective than simvastatin 10 mg and pravastatin 20 mg in reducing LDL-C, total-C, triglycerides and apo B. In several multicentre, double blind studies in patients with hypercholesterolaemia, atorvastatin was compared to other HMG-CoA reductase inhibitors.

After randomisation, patients were treated with atorvastatin 10 mg per day or the recommended starting dose of the comparative agent. Increasing the dosage of Imogam Rabies (Rabies Immune Globulin (Human))- FDA resulted in more patients reaching target LDL-C goals.

Prevention of cardiovascular disease. Patients with a history of previous myocardial infarction or angina were excluded. In this randomised, double blind, placebo controlled study patients were treated with antihypertensive therapy (goal BP The primary endpoint examined in ASCOT was the rate ricini oleum fatal coronary heart disease or nonfatal myocardial infarction over 3.

These coronary events occurred in 1. Although this difference was statistically significant for the whole trial population, this difference was not statistically significant in specified subgroups such as diabetes, patients with left ventricular hypertrophy (LVH), previous vascular disease, or metabolic syndrome. There was no statistically significant reduction in the rate of total mortality, CV mortality or heart failure in the atorvastatin treated group compared to placebo.

Noninsulin dependent diabetes mellitus (NIDDM). A 26 week randomised, double blind, comparator study in NIDDM subjects showed that atorvastatin is effective in dyslipidaemic patients with NIDDM. Lipitor has also been shown zetia ezetimibe reduce LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to other lipid lowering medication.

In an uncontrolled compassionate use study, 29 patients aged 6 to 37 years with homozygous familial hypercholesterolaemia received maximum daily doses of 20 to 80 mg of atorvastatin.

Experience in paediatric patients has been limited to patients with homozygous FH. A constant proportion of atorvastatin is absorbed intact. However, LDL-C reduction is the same regardless of the time of day of drug administration (see Section 4. The mean volume of distribution Imogam Rabies (Rabies Immune Globulin (Human))- FDA atorvastatin is about 400 litres.

Based on observations in rats, atorvastatin is likely to be secreted in human milk (see Section 4. In humans, Didrex (Benzphetamine)- FDA is extensively metabolised to ortho- and para-hydroxylated derivatives. In vitro inhibition of HMG-CoA reductase by ortho- and para-hydroxylated Imogam Rabies (Rabies Immune Globulin (Human))- FDA is equivalent to that of atorvastatin. In vitro studies suggest the importance of atorvastatin metabolism by CYP 3A4, consistent with increased plasma concentrations of atorvastatin in Imogam Rabies (Rabies Immune Globulin (Human))- FDA following coadministration with erythromycin, a known inhibitor of this isozyme (see Section 4.

Further...

Comments:

There are no comments on this post...